Core Viewpoint - The 2025 National Medical Insurance Drug List has been released, including 114 new drugs, with a focus on innovative drugs and significant improvements in coverage for key areas such as cancer, chronic diseases, and rare diseases [4][5][10]. Group 1: New Drug Inclusion - A total of 15 A-share pharmaceutical companies announced that their products have been included in the new drug list, particularly benefiting innovative drug companies [7]. - Zai Lab's drug, Jikaxitinib, has been included in the list, which is expected to enhance sales and market accessibility for patients [7]. - Junshi Biosciences has multiple products included, with two new indications for its drug Toripalimab and another drug successfully included in the Class B category [7]. Group 2: Impact on Major Pharmaceutical Companies - Leading companies like Hengrui Medicine have had 10 products included in the new list, with an estimated combined sales of approximately 8.66 billion yuan for 2024 and about 7.55 billion yuan for the first three quarters of 2025 [9]. - Other major players such as Fosun Pharma and Huadong Medicine also have products included, indicating a broad impact across the industry [8]. Group 3: Overall Drug List Changes - The total number of drugs in the directory has increased to 3,253, with 1,857 Western medicines and 1,396 traditional Chinese medicines [5]. - The adjustment marks the eighth update since the establishment of the National Medical Insurance Bureau, reflecting ongoing efforts to enhance drug accessibility and affordability [10].

Group 1 - Heng Rui Pharmaceutical has 9 drugs included in the national medical insurance directory for the first time, with an estimated total sales of approximately 8.66 billion yuan for 2024 and 7.55 billion yuan for the first three quarters of 2025 [5] - Junshi Biosciences' products Tuoyi® and Junshida® have been added to the national medical insurance directory, enhancing patient affordability and market promotion [6] - Huadong Medicine's subsidiary has products included in the national medical insurance and commercial insurance innovative drug directories, expected to aid in market promotion [7] Group 2 - Aidi Pharmaceutical's two innovative HIV drugs have successfully renewed their inclusion in the national medical insurance directory, with specific reimbursement prices set [8] - Fuxing Pharmaceutical has multiple products newly included in the national medical insurance directory, which is anticipated to positively impact future performance [9] - Weichuang Biotechnology's product has been included in the national medical insurance directory, which is expected to enhance market promotion and sales [10] Group 3 - Muxi Co., Ltd. announced a final online issuance rate of 0.03348913% after the mechanism was activated, with a total of 22.83 million shares issued [2] - Doushan New Materials reached a consensus on production reduction in the BOPET industry, although the sustainability of long-term price increases remains uncertain [2] - Guanglian Aviation's controlling shareholder has had the detention lifted, allowing normal operations to resume [3] Group 4 - Jiangjian Co., Ltd. clarified that it bears no obligations for any overdue financial products related to its controlling shareholder, confirming normal operations [4] - Tian Ci Materials' controlling shareholder has committed not to reduce holdings, holding 34.35% of the shares [13] - Annie Co., Ltd. is planning a change in control, with stock resuming trading on December 8 [14]

泽璟制药公告称，2025年12月7日，公司自主研发的盐酸吉卡昔替尼片通过国家医保谈判，被纳入《国 家基本医疗保险、生育保险和工伤保险药品目录（2025年）》，将于2026年1月1日起执行，协议有效期 至2027年12月31日。该药品为1类新药，用于治疗骨髓纤维化等，已获多项指南推荐。其治疗重度斑秃 适应症申请已获受理，治疗活动性强直性脊柱炎达主要疗效终点。此次纳入医保利于销售，对长期经营 有积极影响，预计短期内不影响业绩。 ...

智通财经APP讯，泽璟制药(688266.SH发布公告，2025年12月7日，国家医疗保障局、人力资源和社会 保障部公布了《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》(以下简称"国家医保药品 目录")，公司自主研发的盐酸吉卡昔替尼片通过国家医保谈判，被纳入国家医保药品目录。2025年国家 医保药品目录将于2026年1月1日起执行。 本次盐酸吉卡昔替尼片被纳入国家医保药品目录将有利于产品的销售，对公司的长期经营发展具有积极 影响，预计短期内不会对经营业绩产生重大影响。 ...

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4] Core Viewpoints - The report emphasizes the focus on innovative drugs as the main investment theme for the year, highlighting the potential for recovery in valuations due to numerous upcoming catalysts in the innovative drug sector [5][15] - ZG006 from Zai Lab is highlighted as a promising candidate for small cell lung cancer, with clinical data showing high efficacy and safety, positioning it as a potential Best-in-Class (BIC) drug [5][8][14] Summary by Sections ZG006 - ZG006 is a trispecific antibody developed by Zai Lab, targeting DLL3 and CD3, and has received clinical trial approval from both the FDA and NMPA [8] - Clinical trial results show an overall response rate (ORR) of 60.0% and 66.7% for two dosage groups, with disease control rates (DCR) at 73.3% for both [11][12] - The drug is expected to have a significant market opportunity, especially in the context of its promising clinical data and competitive landscape [14] Industry Perspective - The pharmaceutical index has shown a decline of 0.74% in the recent week, with a year-to-date increase of 15.86%, indicating a relatively stable industry outlook [15] - The report suggests focusing on innovative drugs, manufacturing exports, and aging-related consumption as key investment themes [34][35] - The report identifies several companies to watch, including Xinlitai, Zai Lab, and Heng Rui Medicine, among others, as they are expected to benefit from the ongoing industry trends [37]

北京商报讯（记者 丁宁）12月7日晚间，泽璟制药（688266）发布公告称，12月7日，国家医疗保障 局、人力资源和社会保障部公布了《国家基本医疗保险、生育保险和工伤保险药品目录（2025年）》 （以下简称"国家医保药品目录"），公司自主研发的盐酸吉卡昔替尼片通过国家医保谈判，被纳入国家 医保药品目录。 泽璟制药表示，本次盐酸吉卡昔替尼片被纳入国家医保药品目录将有利于产品的销售，对公司的长期经 营发展具有积极影响，预计短期内不会对经营业绩产生重大影响。 ...

2025 年 12 月 7 日，国家医疗保障局、人力资源和社会保障部公布了《国家 基本医疗保险、生育保险和工伤保险药品目录（2025 年）》（以下简称"国家医 保药品目录"），苏州泽璟生物制药股份有限公司（以下简称"公司"）自主研发 的盐酸吉卡昔替尼片通过国家医保谈判，被纳入国家医保药品目录。2025 年国 家医保药品目录将于 2026 年 1 月 1 日起执行。 证券代码：688266 证券简称：泽璟制药 公告编号：2025-056 苏州泽璟生物制药股份有限公司 关于自愿披露盐酸吉卡昔替尼片纳入 2025 年 国家医保药品目录的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 盐酸吉卡昔替尼片被纳入 2025 年国家医保药品目录体现了国家医疗保障局 对该药物的临床价值、患者获益、创新程度等方面的认可。未来，公司将和各方 紧密配合推进医保政策落地，力争让更多患者获益。 本次盐酸吉卡昔替尼片被纳入 2025 年国家医保药品目录将有利于产品的销 售，有助于公司进一步提高该药物在患者中的可负担性和可及性，有利 ...

证券代码：688266 证券简称：泽璟制药 公告编号：2025-055 苏州泽璟生物制药股份有限公司 关于自愿披露 ZG006 在 2025 年欧洲肿瘤内科学会亚 洲年会（ESMO Asia）发布临床数据及 最新进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 1、苏州泽璟生物制药股份有限公司（以下简称"公司"）自主研发的新药 Alveltamig（代号：ZG006）的临床研究数据及最新进展于 2025 年 12 月 5 日至 7 日召开的欧洲肿瘤内科学会亚洲年会（ESMO Asia）上发布。 2、本次在 2025 年欧洲肿瘤内科学会亚洲年会（ESMO Asia）发布最新临床 数据事项对公司近期业绩不会产生重大影响。由于医药产品具有高科技、高风险、 高附加值的特点，药品前期研发以及产品从研制、临床试验、报批到投产的周期 长、环节多，容易受到一些不确定性因素的影响，公司将及时根据后续进展履行 信息披露义务。敬请广大投资者谨慎决策，注意防范投资风险。 为使各位投资者及时了解公司相关研究成果，现将ZG006的临床数据及 ...

证券之星消息，12月4日，医疗健康（980016）指数报收于6253.16点，涨0.38%，成交141.17亿元，换手 率0.51%。当日该指数成份股中，上涨的有22家，泽璟制药以3.73%的涨幅领涨，下跌的有27家，华大智 造以3.25%的跌幅领跌。 医疗健康（980016）指数十大成份股详情如下： | 医疗健康指数 十大成份股 | | --- | | 证券代码 | 股票简称 | 权重 | 最新价 | 涨跌幅 | 总市值(亿元) | | 所属行业 | | --- | --- | --- | --- | --- | --- | --- | --- | | sh603259 | 药明康德 | 13.66% | 89.59 | 2.25% | | 2673.15 | 医药生物 | | sh600276 | 恒瑞医药 | 11.00% | 61.25 | 0.46% | | 4065.28 | 医药生物 | | sz300760 | 迈瑞医疗 | 7.57% | 200.00 | 0.25% | | 2424.88 | 医药生物 | | sh688271 | 联影医疗 | 4.27% | 128.87 | -0.0 ...

Core Points - The Shanghai Composite Index closed at 3875.79 points, slightly down by 0.06%, with a total trading volume of 1561.665 billion yuan [1] - A total of 56 A-shares have surpassed the half-year line, with notable stocks showing significant deviation rates [1] Summary by Category Market Performance - The Shanghai Composite Index is above the half-year line, indicating a stable market performance [1] - The total trading volume for A-shares today reached 1561.665 billion yuan [1] Notable Stocks - Stocks with the highest deviation rates from the half-year line include: - Huawu Co., Ltd. (300095) with a deviation rate of 12.77% and a price increase of 19.96% [1] - Hengerd (300946) with a deviation rate of 11.14% and a price increase of 20.01% [1] - Yingqu Technology (002925) with a deviation rate of 8.13% and a price increase of 10.02% [1] - Other stocks that have just crossed the half-year line include Ruifeng Bank, Baosheng Co., and Guosheng Zhike, which have smaller deviation rates [1] Detailed Stock Data - A detailed table lists various stocks, their trading performance, turnover rates, half-year line prices, latest prices, and deviation rates, highlighting the performance of each stock [1][2]